Structure via PubChem · Public domain (PubChem)
alvameline
Sign in to saveAlvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.
Chemical data
- Formula
- C9H15N5
- Molecular weight
- 193.25 g/mol
- IUPAC name
- 5-(2-ethyltetrazol-5-yl)-1-methyl-3,6-dihydro-2H-pyridine
- SMILES
- CCN1N=C(N=N1)C2=CCCN(C2)C
- InChIKey
- RNMOMKCRCIRYCZ-UHFFFAOYSA-N
- XLogP
- 0.7
- Polar surface area
- 46.8 Ų
- H-bond donors
- 0
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Mass
- 193.133
Show 4 more facts
- canonical SMILES
- CCN1N=C(N=N1)C2=CCCN(C2)C
- chemical formula
- C₉H₁₅N₅
- Commons category
- Alvameline
- different from
- alverine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Alvameline (Lu 25-109) is a M1 receptor agonist and M2/M3 receptor antagonist that was under investigation for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.
== See also == Milameline Sabcomeline Tazomeline Xanomeline
Excerpted from Wikipedia’s “alvameline” article, available under the CC BY-SA 4.0 licence.